Scarica l'app Stockscreener
37.23
1.80%
0.66
Dopo l'orario di chiusura:
37.23
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché CRNX Giù?
Forum
Previsione
Crinetics Pharmaceuticals Inc Borsa (CRNX) Ultime notizie
Aberdeen Group plc Buys 334,584 Shares of Crinetics Pharmaceuticals, Inc. $CRNX - MarketBeat
Price performance - Yahoo Finance Australia
Indivior, Liquidia, Crinetics top Quant pharma list as Merck scoops up Terns for $6.7B - MSN
Price-Driven Insight from (CRNX) for Rule-Based Strategy - Stock Traders Daily
CRNX Stock Price, Quote & Chart | CRINETICS PHARMACEUTICALS IN (NASDAQ:CRNX) - ChartMill
Crinetics Director Sells 5,000 Shares With Stock Down 4%, but Here's What Matters More - AOL.com
Crinetics Pharmaceuticals Director Sells Shares - intellectia.ai
Crinetics Pharmaceuticals Inc. (CRNX) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
CRNX PE Ratio & Valuation, Is CRNX Overvalued - Intellectia AI
Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
Crinetics Pharma Director Stock SaleMarch 2026 Transaction DetailsNews and Statistics - IndexBox
Crinetics Pharma COO to step down - MSN
Crinetics Pharmaceuticals (NASDAQ:CRNX) Rating Lowered to "Sell" at Wall Street Zen - MarketBeat
Crinetics submits application for acromegaly drug in Brazil By Investing.com - au.investing.com
Crinetics Pharmaceuticals Announces Submission of Marketing Authorization Application in Brazil for Palsonify (Paltusotine) in Acromegaly - Bitget
Vanguard disaggregates holdings; Crinetics (CRNX) parent reports 0 shares - Stock Titan
Crinetics Pharmaceuticals Announces Submission of Marketing Authorization Application in Brazil for Palsonify™ (Paltusotine) in Acromegaly - The Manila Times
Crinetics submits application for acromegaly drug in Brazil - Investing.com
Crinetics Pharmaceuticals Announces Submission of Marketing - GlobeNewswire
Indivior, Liquidia, Crinetics top Quant pharma list as Merck scoops up Terns for $6.7B (XLV:NYSEARCA) - Seeking Alpha
Crinetics Pharmaceuticals (CRNX) Executive Resignation Announced - GuruFocus
Crinetics Pharmaceuticals (NASDAQ:CRNX) Stock Price Down 4.3%Here's Why - MarketBeat
Crinetics Pharmaceuticals, Inc. Announces Resignation of Jeff Knight as Chief Development and Operating Officer, Effective on or About April 10, 2026 - MarketScreener
Crinetics Pharmaceuticals, Inc. Files Form 8-K with SEC: Company Details, Stock Info, and Compliance Data (March 2026) - Minichart
Crinetics Pharmaceuticals chief development and operating officer to resign By Investing.com - Investing.com South Africa
Crinetics Pharmaceuticals chief development and operating officer to resign - Investing.com
Crinetics' Jeff Knight to Resign as Chief Development and Operating Officer - TradingView
Crinetics (NASDAQ: CRNX) COO-level executive Jeff Knight to resign by April 10, 2026 - Stock Titan
Q4 2025 Crinetics Pharmaceuticals Inc Earnings Call Transcript - GuruFocus
Q2 2025 Crinetics Pharmaceuticals Inc Earnings Call Transcript - GuruFocus
Q1 2025 Crinetics Pharmaceuticals Inc Earnings Call Transcript - GuruFocus
Q3 2025 Crinetics Pharmaceuticals Inc Earnings Call Transcript - gurufocus.com
Stock Market Recap: Is Crinetics Pharmaceuticals Inc a stock for growth or value investorsTake Profit & Daily Stock Trend Watchlist - baoquankhu1.vn
Merger Talk: Whats the beta of Crinetics Pharmaceuticals Inc stockWeekly Market Report & Technical Entry and Exit Alerts - baoquankhu1.vn
JPMorgan Chase & Co. Acquires 926,765 Shares of Crinetics Pharmaceuticals, Inc. $CRNX - MarketBeat
CRNX Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Patterns Watch: What is the dividend yield of Crinetics Pharmaceuticals Inc2026 Retail & Weekly Top Gainers Alerts - baoquankhu1.vn
Crinetics Pharmaceuticals (NASDAQ:CRNX) Insider Stephen Betz Sells 10,612 Shares - MarketBeat
Crinetics Pharmaceuticals (NASDAQ:CRNX) CEO Sells $821,429.97 in Stock - MarketBeat
Crinetics Pharmaceuticals Insider Sold Shares Worth $821,513, According to a Recent SEC Filing - marketscreener.com
Crinetics Pharmaceuticals (CRNX) COO sells 9,911 shares for RSU taxes - Stock Titan
Crinetics (NASDAQ: CRNX) CSO sells shares to cover RSU tax - Stock Titan
Crinetics (CRNX) CEO discloses tax-related share sales under 10b5-1 plan - Stock Titan
CRNX (NASDAQ: CRNX) insider sells shares via 10b5-1 and option exercise - Stock Titan
Jim Cramer on Crinetics: “That’s a better spec than Aquestive” - MSN
[144] Crinetics Pharmaceuticals, Inc. SEC Filing - Stock Titan
0.49%
1.47%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):